Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP

Abstract

Febrile neutropenia (FN) is the major toxicity of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen in the treatment of diffuse large B-cell lymphoma (DLBCL). The prediction of neutropenia and FN is mandatory to continue the planned R-CHOP therapy resulting in successful anti-cancer treatment. The clinical features… (More)
DOI: 10.3346/jkms.2014.29.11.1493

Topics

5 Figures and Tables

Cite this paper

@inproceedings{Choi2014PatternsON, title={Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP}, author={Yong Won Choi and Seong Hyun Jeong and Mi Sun Ahn and Hyun Woo Lee and Seok Yun Kang and Jin-Hyuk Choi and U Ram Jin and Joon Seong Park}, booktitle={Journal of Korean medical science}, year={2014} }